173 related articles for article (PubMed ID: 28497076)
1. Molecular Mechanism of
Morsalin S; Yang C; Fang J; Reddy S; Kayarthodi S; Childs E; Matthews R; Rao VN; Reddy ESP
J Pharm Sci Pharmacol; 2015 Sep; 2(3):208-216. PubMed ID: 28497076
[TBL] [Abstract][Full Text] [Related]
2. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.
Hermans KG; van der Korput HA; van Marion R; van de Wijngaart DJ; Ziel-van der Made A; Dits NF; Boormans JL; van der Kwast TH; van Dekken H; Bangma CH; Korsten H; Kraaij R; Jenster G; Trapman J
Cancer Res; 2008 Sep; 68(18):7541-9. PubMed ID: 18794142
[TBL] [Abstract][Full Text] [Related]
3. Relationship between ETS Transcription Factor ETV1 and TGF-β-regulated SMAD Proteins in Prostate Cancer.
Oh S; Shin S; Song H; Grande JP; Janknecht R
Sci Rep; 2019 Jun; 9(1):8186. PubMed ID: 31160676
[TBL] [Abstract][Full Text] [Related]
4. Sumoylation of transcription factor ETV1 modulates its oncogenic potential in prostate cancer.
Oh S; Shin S; Janknecht R
Int J Clin Exp Pathol; 2021; 14(7):795-810. PubMed ID: 34367411
[TBL] [Abstract][Full Text] [Related]
5. COP1 is a tumour suppressor that causes degradation of ETS transcription factors.
Vitari AC; Leong KG; Newton K; Yee C; O'Rourke K; Liu J; Phu L; Vij R; Ferrando R; Couto SS; Mohan S; Pandita A; Hongo JA; Arnott D; Wertz IE; Gao WQ; French DM; Dixit VM
Nature; 2011 May; 474(7351):403-6. PubMed ID: 21572435
[TBL] [Abstract][Full Text] [Related]
6. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
Rahim S; Minas T; Hong SH; Justvig S; Çelik H; Kont YS; Han J; Kallarakal AT; Kong Y; Rudek MA; Brown ML; Kallakury B; Toretsky JA; Üren A
PLoS One; 2014; 9(12):e114260. PubMed ID: 25479232
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3 proteins modulate the ETS transcription factor ETV1 in prostate cancer.
Oh S; Shin S; Lightfoot SA; Janknecht R
Cancer Res; 2013 Aug; 73(16):5110-9. PubMed ID: 23774214
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis.
He Y; Mi J; Olson A; Aldahl J; Hooker E; Yu EJ; Le V; Lee DH; Kim WK; Robins DM; Geradts J; Sun Z
Oncogene; 2020 Apr; 39(16):3276-3291. PubMed ID: 32089544
[TBL] [Abstract][Full Text] [Related]
9. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
[TBL] [Abstract][Full Text] [Related]
10. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
12. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.
Shin S; Kim TD; Jin F; van Deursen JM; Dehm SM; Tindall DJ; Grande JP; Munz JM; Vasmatzis G; Janknecht R
Cancer Res; 2009 Oct; 69(20):8102-10. PubMed ID: 19789348
[TBL] [Abstract][Full Text] [Related]
13. ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells.
Shin S; Oh S; An S; Janknecht R
Oncol Rep; 2013 Jan; 29(1):306-14. PubMed ID: 23076342
[TBL] [Abstract][Full Text] [Related]
14. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.
Chesire DR; Ewing CM; Gage WR; Isaacs WB
Oncogene; 2002 Apr; 21(17):2679-94. PubMed ID: 11965541
[TBL] [Abstract][Full Text] [Related]
15. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
[TBL] [Abstract][Full Text] [Related]
16. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
[TBL] [Abstract][Full Text] [Related]
17. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis.
Kolligs FT; Bommer G; Göke B
Digestion; 2002; 66(3):131-44. PubMed ID: 12481159
[TBL] [Abstract][Full Text] [Related]
18. gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin.
Kolligs FT; Kolligs B; Hajra KM; Hu G; Tani M; Cho KR; Fearon ER
Genes Dev; 2000 Jun; 14(11):1319-31. PubMed ID: 10837025
[TBL] [Abstract][Full Text] [Related]
19. 3D-microenvironments initiate TCF4 expression rescuing nuclear β-catenin activity in MCF-7 breast cancer cells.
Sergio S; Coluccia AML; Lemma ED; Spagnolo B; Vergara D; Maffia M; De Vittorio M; Pisanello F
Acta Biomater; 2020 Feb; 103():153-164. PubMed ID: 31843716
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation.
Gasi D; van der Korput HA; Douben HC; de Klein A; de Ridder CM; van Weerden WM; Trapman J
PLoS One; 2011 Jan; 6(1):e16332. PubMed ID: 21298110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
